ResMed Q3 2024 Adj EPS $2.13 Beats $1.91 Estimate, Sales $1.200B Beat $1.167B Estimate
Portfolio Pulse from Benzinga Newsdesk
ResMed (NYSE:RMD) reported Q3 2024 adjusted EPS of $2.13, surpassing the $1.91 estimate, with sales of $1.200B also beating the $1.167B estimate, marking a 7.44% increase over the previous year.
April 25, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed reported a strong Q3 2024 with adjusted EPS and sales exceeding analyst estimates, indicating robust financial health and growth.
ResMed's earnings and sales beat not only demonstrates the company's ability to outperform market expectations but also suggests a positive outlook for its financial health and operational efficiency. Such positive earnings reports typically lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100